Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Director departure
Appointed director
Cyclerion Therapeutics, Inc. (CYCN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 4 MCGUIRE TERRANCE (Director) has filed a Form 4 on Cyclerion Therapeutics, Inc.
Txns: Sold 8 shares @ $3.395, valued at $27.2
07/28/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/19/2023 8-K Quarterly results
07/12/2023 8-K Other Events  Interactive Data
06/09/2023 PREM14A Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
06/01/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement CAMBRIDGE, Mass., June 1, 2023"
05/25/2023 D Form D - Notice of Exempt Offering of Securities:
05/25/2023 8-K Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial ...
Docs: "Articles of Amendment to the Restated Articles of Organization of the Company, as amended"
05/23/2023 SC 13D/A Hecht Peter M has filed a Schedule 13D for Cyclerion Therapeutics, Inc.
05/22/2023 4 Hecht Peter M (CEO) has filed a Form 4 on Cyclerion Therapeutics, Inc.
Txns: Granted 225,000 shares @ $8.68, valued at $2M
Granted 351,037 convertible preferred @ $0
05/15/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Articles of Amendment to the Restated Articles of Organization of the Company",
"CAMBRIDGE, Mass., May 15, 2023"
05/12/2023 SC 13D/A Hecht Peter M has filed a Schedule 13D for Cyclerion Therapeutics, Inc.
04/03/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/03/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement CAMBRIDGE, Mass., April 3, 2023"
04/03/2023 SC 13D/A Hecht Peter M has filed a Schedule 13D for Cyclerion Therapeutics, Inc.
03/22/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/22/2023 10-K Annual Report for the period ended December 31, 2022
03/22/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Cyclerion Reports Corporate Update and Full Year 2022 Financial Results CAMBRIDGE, Mass., March 22, 2023"
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/13/2023 SC 13G Slate Path Capital LP reports a 16.5% stake in Cyclerion Therapeutics, Inc.
11/29/2022 8-K Quarterly results
11/22/2022 8-K Quarterly results
11/21/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/21/2022 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
10/06/2022 8-K Quarterly results
09/30/2022 8-K Quarterly results
08/10/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
Docs: "Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes and Cognitive Impairment Associated with Schizophrenia Study in Alzheimer’s Disease with vascular pathology enrollment ongoing Appointed Steven E. Hyman, M.D. to its Board of Directors CAMBRIDGE, Mass., Aug. 9, 2022"
07/28/2022 8-K Quarterly results
07/27/2022 4/A Hyman Steven (Director) has filed a Form 4 on Cyclerion Therapeutics, Inc.
Txns: Granted 57,753 options to buy @ $0.78, valued at $45k
07/26/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy